Three Weekly Irinotecan for Refractory/Relapsed Small Cell Lung Cancer

被引：0
|
作者：
Nutalapati, S. [1 ]
Yan, D. [1 ]
Morgan, R. [1 ]
Chauhan, A. [1 ]
机构：
[1] Univ Kentucky, Lexington, KY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
high-grade neuroendocrine carcinoma; Small cell lung cancer; Irinotecan;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P63.14
引用
收藏
页码：S1188 / S1188
页数：1
相关论文
共 50 条
  • [41] Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer
    Kubota, K
    Nishiwaki, Y
    Kakinuma, R
    Hojo, F
    Matsumoto, T
    Ohmatsu, H
    Sekine, I
    Yokozaki, M
    Goto, K
    Ebi, N
    Kodama, T
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 292 - 296
  • [42] A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
    Agelaki, S.
    Kontopodis, E.
    Kotsakis, A.
    Chandrinos, V.
    Bompolaki, I.
    Zafeiriou, Z.
    Papadimitraki, E.
    Stoltidis, D.
    Kalbakis, K.
    Georgoulias, V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 45 - 51
  • [43] Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study
    Ichiki, M
    Gohara, R
    Rikimaru, T
    Kitajima, T
    Fujiki, R
    Shimada, A
    Aizawa, H
    CHEMOTHERAPY, 2003, 49 (04) : 200 - 205
  • [44] Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer
    Nakanishi, Y
    Takayama, K
    Takano, K
    Inoue, K
    Osaki, S
    Wataya, H
    Takaki, Y
    Minami, T
    Kawasaki, M
    Hara, N
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (04): : 399 - 402
  • [45] PACLITAXEL AND IRINOTECAN IN PLATINUM REFRACTORY OR RESISTANT SMALL CELL LUNG CANCER: A GALICIAN LUNG CANCER GROUP EXPERIENCE.
    Javier Afonso-Afonso, F.
    Vazquez-Estevez, Sergio
    Casal Rubio, Joaquin
    Firvida Perez, Xose Luis
    Lazaro, Martin
    Lopez Jato, Cristina
    Campos, B.
    Huidobro, G.
    Areses, Mc
    Garcia Cid, Noelia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S635 - S635
  • [46] A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small-cell lung cancer (SCLC).
    Negoro, S
    Uejima, H
    Takeda, K
    Miyazaki, M
    Takihuji, N
    Hirashima, T
    Matsui, K
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [47] Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study
    Ishimoto, Osamu
    Sugawara, Shunichi
    Inoue, Akira
    Maemondo, Makoto
    Nukiwa, Toshihiro
    RESPIRATORY INVESTIGATION, 2015, 53 (04) : 156 - 160
  • [48] Epirubicin combined with ifosfamide in relapsed or refractory small cell lung cancer (SCLC) patients
    Jacot, William
    Molinier, Olivier
    Colinet, Benoit
    Bozonnat, Marie-Cecile
    Quantin, Xavier
    Gervais, Radj
    Pujol, Jean-Louis
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 233
  • [49] A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC).
    Gandhi, Leena
    Heist, Rebecca Suk
    Lucca, Joan Vern
    Temel, Jennifer S.
    Fidias, Panos
    Morse, Linda K.
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
    Steino, Anne
    He, Guangan
    Zhai, Beibei
    Bacha, Jeffrey
    Lu, Shun
    Brown, Dennis
    Daugaard, Mads
    Siddik, Zahid
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1275 - S1276
12345